Contineum Therapeutics, Inc. (CTNM): R&D Expense
$51.52M
Year ended 2025-12-31
$48.10M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.52M | +34.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $38.42M | +39.2% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $27.60M | n/a | 2025-03-06, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $51.52M | +34.1% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Annexon, Inc. (ANNX) | 2025-12-31 | $184.70M | +54.6% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $117.33M | -3.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $102.93M | +28.5% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $12.74M | -69.7% |
Compare CTNM, TNXP, ANNX, ALT side by side · Screen every company in Pharmaceutical Preparations ↗